HPV Vaccination and the Risk of Invasive Cervical Cancer
- PMID: 32997908
- DOI: 10.1056/NEJMoa1917338
HPV Vaccination and the Risk of Invasive Cervical Cancer
Abstract
Background: The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV) vaccine in preventing high-grade cervical lesions have been shown. However, data to inform the relationship between quadrivalent HPV vaccination and the subsequent risk of invasive cervical cancer are lacking.
Methods: We used nationwide Swedish demographic and health registers to follow an open population of 1,672,983 girls and women who were 10 to 30 years of age from 2006 through 2017. We assessed the association between HPV vaccination and the risk of invasive cervical cancer, controlling for age at follow-up, calendar year, county of residence, and parental characteristics, including education, household income, mother's country of birth, and maternal disease history.
Results: During the study period, we evaluated girls and women for cervical cancer until their 31st birthday. Cervical cancer was diagnosed in 19 women who had received the quadrivalent HPV vaccine and in 538 women who had not received the vaccine. The cumulative incidence of cervical cancer was 47 cases per 100,000 persons among women who had been vaccinated and 94 cases per 100,000 persons among those who had not been vaccinated. After adjustment for age at follow-up, the incidence rate ratio for the comparison of the vaccinated population with the unvaccinated population was 0.51 (95% confidence interval [CI], 0.32 to 0.82). After additional adjustment for other covariates, the incidence rate ratio was 0.37 (95% CI, 0.21 to 0.57). After adjustment for all covariates, the incidence rate ratio was 0.12 (95% CI, 0.00 to 0.34) among women who had been vaccinated before the age of 17 years and 0.47 (95% CI, 0.27 to 0.75) among women who had been vaccinated at the age of 17 to 30 years.
Conclusions: Among Swedish girls and women 10 to 30 years old, quadrivalent HPV vaccination was associated with a substantially reduced risk of invasive cervical cancer at the population level. (Funded by the Swedish Foundation for Strategic Research and others.).
Copyright © 2020 Massachusetts Medical Society.
Comment in
-
Improving Radiation Therapy for Cervical Cancer.Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):841-848. doi: 10.1016/j.ijrobp.2021.12.006. Int J Radiat Oncol Biol Phys. 2022. PMID: 35190051 No abstract available.
Similar articles
-
Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.Int J Cancer. 2016 Jun 15;138(12):2867-74. doi: 10.1002/ijc.30035. Epub 2016 Mar 9. Int J Cancer. 2016. PMID: 26856527 Free PMC article.
-
Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.JAMA. 2014 Feb 12;311(6):597-603. doi: 10.1001/jama.2014.95. JAMA. 2014. PMID: 24519299
-
Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.J Natl Cancer Inst. 2013 Apr 3;105(7):469-74. doi: 10.1093/jnci/djt032. Epub 2013 Mar 13. J Natl Cancer Inst. 2013. PMID: 23486550 Free PMC article.
-
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000. BioDrugs. 2011. PMID: 21942919 Review.
-
A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada.J Obstet Gynaecol Can. 2018 Dec;40(12):1635-1645. doi: 10.1016/j.jogc.2018.05.024. Epub 2018 Oct 16. J Obstet Gynaecol Can. 2018. PMID: 30341021 Review.
Cited by
-
Human papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant.J Cancer Surviv. 2024 Nov 18. doi: 10.1007/s11764-024-01709-w. Online ahead of print. J Cancer Surviv. 2024. PMID: 39556189
-
Understanding the relationship between breast cancer, immune checkpoint inhibitors, and gut microbiota: a narrative review.Transl Breast Cancer Res. 2024 Oct 21;5:31. doi: 10.21037/tbcr-24-14. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534584 Free PMC article. Review.
-
Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden setting.J Natl Cancer Inst Monogr. 2024 Nov 1;2024(67):379-386. doi: 10.1093/jncimonographs/lgae039. J Natl Cancer Inst Monogr. 2024. PMID: 39529530 Free PMC article.
-
Awareness of the Link Between Human Papilloma Virus Infection and Head and Neck Cancer Among the General Population and Practitioners: A Literature Review.Cancers (Basel). 2024 Oct 22;16(21):3556. doi: 10.3390/cancers16213556. Cancers (Basel). 2024. PMID: 39517997 Free PMC article. Review.
-
Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.Front Pharmacol. 2024 Oct 21;15:1476256. doi: 10.3389/fphar.2024.1476256. eCollection 2024. Front Pharmacol. 2024. PMID: 39498342 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical